Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Experimental study of radioimmunotherapy versus chemotherapy for colorectal cancer.

de Jong GM, Bleichrodt RP, Eek A, Oyen WJ, Boerman OC, Hendriks T.

Br J Surg. 2011 Mar;98(3):436-41. doi: 10.1002/bjs.7361. Epub 2010 Dec 15.

PMID:
21254023
2.

Adjuvant radioimmunotherapy improves survival of rats after resection of colorectal liver metastases.

de Jong GM, Hendriks T, Eek A, Oyen WJ, Nagtegaal ID, Bleichrodt RP, Boerman OC.

Ann Surg. 2011 Feb;253(2):336-41. doi: 10.1097/SLA.0b013e3181ff313a.

PMID:
21217519
3.

Radioimmunotherapy prevents local recurrence of colonic cancer in an experimental model.

de Jong GM, Boerman OC, Heskamp S, Aarts F, Bleichrodt RP, Hendriks T.

Br J Surg. 2009 Mar;96(3):314-21. doi: 10.1002/bjs.6481.

PMID:
19224516
4.

Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting: preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial.

Behr TM, Memtsoudis S, Vougioukas V, Liersch T, Gratz S, Schmidt F, Lorf T, Post S, Wörmann B, Hiddemann W, Ringe B, Becker W.

Anticancer Res. 1999 Jul-Aug;19(4A):2427-32.

PMID:
10470170
6.

Timing of adjuvant radioimmunotherapy after cytoreductive surgery in experimental peritoneal carcinomatosis of colorectal origin.

Aarts F, Koppe MJ, Hendriks T, van Eerd JE, Oyen WJ, Boerman OC, Bleichrodt RP.

Ann Surg Oncol. 2007 Feb;14(2):533-40. Epub 2006 Nov 23.

PMID:
17122992
7.

Radioimmunotherapy and colorectal cancer.

Koppe MJ, Bleichrodt RP, Oyen WJ, Boerman OC.

Br J Surg. 2005 Mar;92(3):264-76. Review.

PMID:
15739250
8.

A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.

Wong JYC, Chu DZ, Yamauchi DM, Williams LE, Liu A, Wilczynski S, Wu AM, Shively JE, Doroshow JH, Raubitschek AA.

Clin Cancer Res. 2000 Oct;6(10):3855-63.

9.

Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft.

Kraeber-Bodéré F, Saï-Maurel C, Campion L, Faivre-Chauvet A, Mirallié E, Chérel M, Supiot S, Barbet J, Chatal JF, Thédrez P.

Mol Cancer Ther. 2002 Feb;1(4):267-74.

10.

The effects of adjuvant experimental radioimmunotherapy and hyperthermic intraperitoneal chemotherapy on intestinal and abdominal healing after cytoreductive surgery for peritoneal carcinomatosis in the rat.

Aarts F, Bleichrodt RP, de Man B, Lomme R, Boerman OC, Hendriks T.

Ann Surg Oncol. 2008 Nov;15(11):3299-307. doi: 10.1245/s10434-008-0070-4. Epub 2008 Aug 19.

PMID:
18712445
11.

Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.

Brouwers AH, van Eerd JE, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH, Boerman OC.

J Nucl Med. 2004 Feb;45(2):327-37.

12.

Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents.

Pedley RB, Boden JA, Boden R, Boxer GM, Flynn AA, Keep PA, Begent RH.

Cancer Res. 1996 Jul 15;56(14):3293-300.

13.

Benefits of combined radioimmunotherapy and anti-angiogenic therapy in a liver metastasis model of human colon cancer cells.

Li XF, Kinuya S, Yokoyama K, Koshida K, Mori H, Shiba K, Watanabe N, Shuke N, Michigishi T, Tonami N.

Eur J Nucl Med Mol Imaging. 2002 Dec;29(12):1669-74. Epub 2002 Oct 2.

PMID:
12458402
14.

High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.

Behr TM, Béhé M, Stabin MG, Wehrmann E, Apostolidis C, Molinet R, Strutz F, Fayyazi A, Wieland E, Gratz S, Koch L, Goldenberg DM, Becker W.

Cancer Res. 1999 Jun 1;59(11):2635-43.

15.

Radioimmunotherapy of small-volume disease of metastatic colorectal cancer.

Behr TM, Liersch T, Greiner-Bechert L, Griesinger F, Béhé M, Markus PM, Gratz S, Angerstein C, Brittinger G, Becker H, Goldenberg DM, Becker W.

Cancer. 2002 Feb 15;94(4 Suppl):1373-81.

16.

In vitro and preclinical targeted alpha therapy for melanoma, breast, prostate and colorectal cancers.

Allen BJ, Rizvi S, Li Y, Tian Z, Ranson M.

Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):139-46.

PMID:
11418311
17.

In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancer.

Almqvist Y, Steffen AC, Tolmachev V, Divgi CR, Sundin A.

Nucl Med Biol. 2006 Nov;33(8):991-8.

PMID:
17127172
18.

Radioimmunotherapy of colorectal cancer liver metastases: combination with radiotherapy.

Buchegger F, Roth A, Allal A, Dupertuis YM, Slosman DO, Delaloye AB, Mach JP.

Ann N Y Acad Sci. 2000 Jun;910:263-9; discussion 269-70. Review.

PMID:
10911919
19.

Radioimmunotherapy of prostate cancer: does tumor size matter?

Scott AM.

J Clin Oncol. 2005 Jul 20;23(21):4567-9. Epub 2005 Apr 18. No abstract available.

PMID:
15837975
20.

Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies.

Behr TM, Sharkey RM, Juweid ME, Dunn RM, Ying Z, Zhang CH, Siegel JA, Goldenberg DM.

J Nucl Med. 1997 Mar;38(3):409-18.

Supplemental Content

Support Center